Your session is about to expire
← Back to Search
Low dose RLS103 for Social Anxiety Disorder
Study Summary
This trial is testing a new drug to see if it can help people with social anxiety disorder during a public speaking challenge.
- Social Anxiety Disorder
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What potential risks do individuals face when using Low dose RLS103?
"Low dose RLS103 has limited evidence for both safety and efficacy, so it was given a rating of 1."
How many participants are enrolled in this clinical experiment?
"Affirmative. According to clinicaltrials.gov, the medical trial initiated on May 18th 2022 is still in a period of recruitment and requires 30 participants from 3 distinct locations."
Is this research endeavor currently recruiting participants?
"That is correct. Clinicaltrials.gov reports that this clinical trial, which was initiated on May 18th 2022, requires 30 participants at 3 different medical centres and is still actively recruiting patients."
Is this research seeking to include participants that are over 40 years old?
"This study requires that potential participants be aged between 18 and 65. In addition, there are 111 clinical trials available for minors and 274 specifically catering to patients over the age of retirement."
What are the criteria to be eligible for participation in this trial?
"This medical trial is recruiting 30 participants aged 18-65 who suffer from anxiety disorders. In order to be considered for enrollment, potential study members must sign an ICF (Informed Consent Form) and abide by a range of other criteria including being non-smokers with no nicotine use in the prior month, having a LSAS total score ≥75 and HAM-D 17 Score <18 at Screening, BMI between 18 - 32 kg/m2 and weight over 50kg, negative viral serology test results HIV1/HIV2 HBV HCV , female subjects of childbearing capacity must commit to effective contraception during trial duration"
Share this study with friends
Copy Link
Messenger